XML 18 R7.htm IDEA: XBRL DOCUMENT v3.26.3
Organization
9 Months Ended
Sep. 30, 2026
Organization  
Organization

Note 1. Organization

Description of Business

AEON Biopharma, Inc. (“AEON” or the “Company”) is a biopharmaceutical company advancing its botulinum toxin complex, ABP-450, as a full-label therapeutic biosimilar to BOTOX® (onabotulinumtoxinA). The Company is headquartered in Aliso Viejo, California.

On July 21, 2023 (the “Closing Date”), the Company completed the acquisition of AEON Biopharma Sub, Inc. (formerly known as AEON Biopharma, Inc.) (“Old AEON”) pursuant to the definitive agreement dated December 12, 2022 (the “Business Combination Agreement”), as amended April 27, 2023, by and among Priveterra Acquisition Corp. (“Priveterra”), Priveterra’s wholly-owned subsidiary, Priveterra Merger Sub, Inc., and Old AEON (the “Merger”). On the Closing Date, Old AEON merged with Priveterra Merger Sub, Inc., with Old AEON surviving the merger as a wholly-owned subsidiary of the Company. Also on the Closing Date, the Company changed its name from “Priveterra Acquisition Corp.” to “AEON Biopharma, Inc.” and is referred to herein as “AEON,” or the “Company.”

The Company’s Class A common stock is trading on NYSE American under the symbol “AEON.”

Liquidity and Going Concern

The accompanying condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern. The Company has experienced recurring losses from operations and has negative cash flows from operations since its inception. As of September 30, 2026, the Company reported cash and cash equivalents of $11.4 million and an accumulated deficit of $481.3 million. The Company expects to incur losses and use cash in its operations for the foreseeable future.

The Company is developing ABP-450 as a proposed full-label therapeutic biosimilar to BOTOX® through submission of a BLA under Section 351(k), using BOTOX® as the proposed reference product for all of the indications for which BOTOX® is approved other than the cosmetic uses for which the Company does not hold development or commercialization rights.

On August 14, 2024, the Company entered into an “at-the-market” sales agreement with Leerink Partners LLC (“Leerink Partners”) relating to an at-the-market offering program (the “ATM”), pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of common stock, registered pursuant to a shelf registration statement on Form S-3 (No. 333-281562) (as amended and supplemented, the “Registration Statement”) that the Securities and Exchange Commission (the “SEC”) declared effective on August 21, 2024, having aggregate gross proceeds of up to $50.0 million through Leerink Partners as sales agent. Any sales by the Company pursuant to the Registration Statement, including any sales pursuant to the ATM, will be subject to any limits imposed under applicable law, including General Instructions I.B.1 and I.B.6 of Form S-3. Leerink Partners is entitled to a commission at a rate equal to 3.0% of the gross proceeds from sales of shares of common stock under the ATM. No shares were issued under the ATM during the three months ended September 30, 2026. For the nine months ended September 30, 2026, there were 2,282,929 shares issued under the ATM for net proceeds of $2.6 million. As of September 30, 2026, the cumulative shares issued under the ATM were 2,661,939 shares and net proceeds of approximately $3.0 million were received. Although the ATM agreement provides for aggregate gross sales of up to $50.0 million, the Company’s ability to make additional sales under the ATM is subject to applicable Form S-3 limitations, the continued availability of an effective registration statement, contractual restrictions, market conditions and other factors. Accordingly, the remaining nominal program amount should not be viewed as committed or currently available financing. The Company may cancel its at-the-market program at any time upon prior notice, pursuant to its terms.

On November 12, 2025, the Company entered into a Securities Purchase Agreement with certain investors whereby the Company issued and sold to the investors certain PIPE Shares, PIPE Pre-Funded Warrants, PIPE Warrants and True-Up Warrants (each, as defined below) for total gross proceeds of $6.0 million. The Company received gross proceeds of $1.8 million and $4.2 million upon the first closing on November 18, 2025 (the “First Closing”) and the second closing on January 27, 2026 (the “Second Closing”), respectively. See Note 4 Private Placement Financing for additional information.

On November 12, 2025, the Company entered into a Term Sheet with Daewoong (the “Term Sheet”) relating to the exchange (the “Exchange”) of the outstanding senior secured convertible notes of the Company held by Daewoong of $5.0 million and $10.0 million in principal with maturity dates of March 2027 and April 2027, respectively (the “Existing Notes”). On December 15, 2025, the Company entered into an agreement with Daewoong (the “Exchange Agreement”) consistent with the terms of the Term Sheet pursuant to which the Existing Notes held by Daewoong would be exchanged for (i) newly issued shares of common stock of the Company equal to (x) the principal and accrued interest of the Existing Notes as of the closing of the Exchange less (y) the principal amount of the New Convertible Note (as defined below), divided by $1.00, and then multiplied by 1.3 (and rounded down to the nearest whole share of common stock) and/or pre-funded warrants to purchase shares of common stock (the “Daewoong Pre-Funded Warrants”) in lieu of any shares of common stock that would result in Daewoong’s beneficial ownership of common stock exceeding 49.99% (the “Exchange Shares”), (ii) a new senior secured convertible note for $1.5 million (the “New Convertible Note”), and (iii) warrants to purchase up to 8.0 million shares of common stock at an exercise price of $1.09392 per share (the “Daewoong Warrants”). The Daewoong Warrants, which contain the same terms as the PIPE Warrants (as defined below), may only be exercised for cash. The Daewoong Warrants are immediately exercisable after issuance and may be exercised at any time until the five-year anniversary of the Second Closing. See Note 5 Daewoong Convertible Notes for additional information.

On July 13, 2026, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as representative of the several underwriters named therein (the “Representative”), relating to the Company’s underwritten public offering (the “2026 Offering”) of (i) 17,851,599 shares of common stock at a combined public offering price of $0.3221 per share and accompanying Milestone Warrants (as defined below) and (ii) pre-funded warrants to purchase 24,837,008 shares of common stock (the “2026 Pre-Funded Warrants”) at a combined public offering price of $0.3220 per 2026 Pre-Funded Warrant and accompanying Milestone Warrants. Each share of common stock and each 2026 Pre-Funded Warrant was accompanied by one two-year milestone warrant (the “Two-Year Milestone Warrants”) and one five-year milestone warrant (the “Five-Year Milestone Warrants” and, together with the Two-Year Milestone Warrants, the “Milestone Warrants”), representing 200% aggregate warrant coverage. The 2026 Offering closed on July 15, 2026. In July 2026, the Company received aggregate net proceeds of approximately $13.7 million from the 2026 Offering and the subsequent over-allotment closing. See Note 3 Public Offering for additional information.

On September 30, 2026, the Company announced receipt of the official minutes from its BPD Type 2b meeting with the FDA, which satisfied the acceleration condition of the Two-Year Milestone Warrants issued in the 2026 Offering. As a result, the Two-Year Milestone Warrants expire on November 16, 2026, unless earlier exercised. On November 2, 2026, the Company amended the Two-Year Milestone Warrants to lower the exercise price from $0.3221 to $0.20 per share of common stock and from $0.3220 to $0.1999 per pre-funded warrant and received exercise notices accounting for approximately $6.2 million in gross proceeds. Refer to Note 10 Subsequent Events for additional information.

The commencement of additional studies, preparation for future FDA meetings and any further development or commercialization of ABP-450 would require additional funding in the form of equity financings or debt. There can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be commercially acceptable. Furthermore, the use of equity as a source of financing would dilute existing stockholders. The Company currently expects its existing cash and cash equivalents to fund operations into the second quarter of 2027, which is less than one year from the date these condensed consolidated financial statements are issued. As a result of these conditions, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that these condensed consolidated financial statements are issued.

This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of the Company’s liabilities and commitments in the normal course of business. These condensed consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty, including any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

The Company’s future operations are highly dependent on a combination of factors, including (1) the success of its research and development programs; (2) the timely and successful completion of any additional financing; (3) the development of competitive therapies by other biotechnology and pharmaceutical companies; (4) the Company’s ability to manage growth of the organization; (5) the Company’s ability to protect its technology and products; and, ultimately, (6) regulatory approval and successful commercialization and market acceptance of its product candidates.